CytoSorbents Corporation reported its financial results for the first quarter of 2025, highlighting a slight decrease in product sales. Q1 2025 product sales amounted to $8.7 million, representing a 3% year-over-year decrease. Despite this decline, on a constant currency basis, sales were flat. The company experienced strong performance from international distribution and other direct sales countries, which significantly offset the disruption in German direct sales. This disruption was due to a proactive reorganization and strategic realignment of the German sales team and strategy during the quarter. The company aims to return to growth in Germany in the second half of 2025, following two consecutive years of flat sales. The product gross margin remained steady at 71%, consistent with the average from 2024. CytoSorbents is also making significant operational progress, with a focus on managing its total core business towards near breakeven in the second half of 2025. The company continues to leverage its platform blood purification technology, with two main products designed for the treatment of life-threatening conditions in the ICU and cardiac surgery. In 2024, CytoSorbents recorded core product sales of $35.6 million. CytoSorbents remains committed to addressing operational challenges and executing strategic initiatives to drive future growth and profitability.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.